Product Details for NDA 212614
TRIJARDY XR (EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE)
5MG;2.5MG;1GM
Marketing Status: Prescription
10MG;5MG;1GM
Marketing Status: Prescription
12.5MG;2.5MG;1GM
Marketing Status: Prescription
25MG;5MG;1GM
Marketing Status: Prescription
5MG;2.5MG;1GM
Marketing Status: Prescription
Active Ingredient: EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 5MG;2.5MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N212614
Product Number: 001
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
TRIJARDY XR (EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE)
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 5MG;2.5MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N212614
Product Number: 001
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
10MG;5MG;1GM
Marketing Status: Prescription
Active Ingredient: EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 10MG;5MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N212614
Product Number: 002
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
TRIJARDY XR (EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE)
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 10MG;5MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N212614
Product Number: 002
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
12.5MG;2.5MG;1GM
Marketing Status: Prescription
Active Ingredient: EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 12.5MG;2.5MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N212614
Product Number: 003
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
TRIJARDY XR (EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE)
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 12.5MG;2.5MG;1GM
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N212614
Product Number: 003
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
25MG;5MG;1GM
Marketing Status: Prescription
Active Ingredient: EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 25MG;5MG;1GM
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N212614
Product Number: 004
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information
Proprietary Name: TRIJARDY XR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 25MG;5MG;1GM
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N212614
Product Number: 004
Approval Date: Jan 27, 2020
Applicant Holder Full Name: BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Marketing Status: Prescription
Patent and Exclusivity Information